Developing therapeutics to elevate egg quality for IVF success
Our mission: turning every IVF attempt into a success story
For women under 35, only 3 in 10 will have a child after one IVF attempt. For those aged 40-42, the success rate drops to 1 in 10. Each failed cycle further decreases the chance of future success, and causes repeated stress for both partners, including financial, physical, psychological, and professional pressures.
At Ovo Labs, we create technologies that boost egg quality to enhance IVF success.
Pioneered by renowned fertility experts
Ovo Labs was co-founded by Melina Schuh (PhD) and Agata Zielinska (MD PhD). Two leading experts in the field of female fertility who have authored several landmark publications over the past decades and have received prestigious awards for their contributions to understanding why fertility in women declines with age.
Prof. Dr. Melina Schuh
Dr. Agata Zielinska
Our technology
At Ovo Labs, we are developing therapeutics that protect eggs from defects that can accumulate as women age. In this way, our technology aims to extend the timeline when the chances of conception are high. We are currently advancing three such egg rejuvenation therapeutics through the clinical development pipeline.
Together, these therapeutics have the potential to increase IVF success rates by 20-30% for women below 35 and by 3-5 times for women aged 35-45.
